CD274 and neoplasm: Preclinical studies demonstrate this synergy in TNBC models; alpelisib combined with anti‐PD‐1 antibodies reduced tumour growth by downregulating p66Shc‐dependent ROS and enhancing CD8+ T‐cell infiltration [195], while AZD5363, combined with anti‐PD‐L1, delayed castration‐resistant PCa progression in vivo by mitigating ROS‐mediated immunosuppression [196].